Solid Biosciences (SLDB) announced that SGT-003, the Company’s investigational gene therapy for Duchenne muscular dystrophy, has been granted an Innovation Passport under the new Innovative Licensing and Access Pathway, ILAP. The Innovation Passport is the entry point for the ILAP, which aims to accelerate time to market and facilitate patient access to new medicines in the UK. The Innovation Passport activates the MHRA and the ILAP partner agencies to develop a product-specific roadmap for regulatory and development milestones.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences price target lowered to $11 from $13 at JPMorgan
- Solid Biosciences price target lowered to $14 from $16 at Citi
- Solid Biosciences Faces Regulatory and Financial Challenges Amid FDA Disruptions
- Solid Biosciences’ SGT-003 Therapy Shows Promising Efficacy and Safety, Earning a Buy Rating
- Solid Biosciences price target lowered to $9 from $10 at Barclays